Clinical and molecular biomarkers predicting response to PARP inhibitors in ovarian cancer.

Takahiro Nozaki Ikuko Sakamoto Keiko Kagami Kenji Amemiya Yosuke Hirotsu Hitoshi Mochizuki Masao Omata

Published in: Journal of gynecologic oncology (2024)

We found that HRRm can be a useful biomarker for predicting the effects of PARP inhibitors in treating ovarian cancer and that the PFI can also be useful in recurrent ovarian cancer.

Keyphrases

dna damage
dna repair
oxidative stress
single molecule